LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Adams, Andrew C ^a   Halstead, Carolyn A ^a   Hansen, Barbara C ^b   Irizarry, Armando R ^a   Martin, Jennifer A ^a   Myers, Sharon R ^a   Reynolds, Vincent L ^a   Smith, Holly W ^a   Wroblewski, Victor J ^a   Kharitonenkov, Alexei ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; LEPTIN; LY 2405319; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; LY2405319;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; METABOLIC REGULATION; MOUSE; NONHUMAN; RHESUS MONKEY; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; ANIMAL; BLOOD; CALORIC INTAKE; DISEASE COURSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; WEIGHT REDUCTION;

ANIMALIA; MACACA MULATTA; PRIMATES;

ADIPOKINES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY INTAKE; FIBROBLAST GROWTH FACTORS; INSULIN; MACACA MULATTA; WEIGHT LOSS;

EID: 84879187565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065763     Document Type: Article

References (23)

1. Moller DE, (2012) Metabolic disease drug discovery- "hitting the target" is easier said than done. Cell Metab 15: 19-24.
2. Tharakan G, Tan T, Bloom S, (2011) Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci 32: 8-15.
3. Nishimura T, Nakatake Y, Konishi M, Itoh N, (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206.
4. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, et al. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297: E1105-1114.
5. Kliewer SA, Mangelsdorf DJ, (2010) Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91: 254S-257S.
6. Kharitonenkov A, Larsen P, (2011) FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 22: 81-86.
7. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635.
8. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, et al. (2012) Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 7: e38438.
9. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027.
10. Veniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, et al. (2012) FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice. PLoS One 7: e40164.
11. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.
12. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, et al. (2012) Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153: 4192-4203.
13. Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, et al. (2012) FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61: 505-512.
14. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, et al. (2013) Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319. PLoS One 8: e58575.
15. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781.
16. Hansen BC, (2012) Investigation and treatment of type 2 diabetes in nonhuman primates. Methods Mol Biol 933: 177-185.
17. Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, et al. (2012) The breadth of FGF21s metabolic actions are governed by FGFR1 in adipose tissue Molecular Metabolism 1.
18. Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 requires βklotho to act in vivo. PLoS One.
19. Murphy M, Samms R, Warner A, Bolborea M, Barrett P, et al. (2012) Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity. J Neuroendocrinol.
20. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, et al. (2012) betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 16: 387-393.
21. Turer AT, Scherer PE, (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55: 2319-2326.
22. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, et al. (2013) Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice. Cell Metab 17: 779-789.
23. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, et al. (2013) An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice. Cell Metab 17: 790-797.